Log in to search using one of your social media accounts:

 

International Mesothelioma Conference Will Kick Off at UCLA

Thoracic surgeon and renowned mesothelioma specialist Dr. Robert Cameron will be hosting the 6th International Symposium on Malignant Pleural Mesothelioma on Saturday, Sept. 24, at the UCLA School of Medicine. Cameron, director of the UCLA Comprehensive Mesothelioma Program, is a global leader in the development of the lung-sparing pleurectomy/decortication surgery and a vocal advocate for military veterans who develop the asbestos-related disease. The conference will cover the latest in mesothelioma therapeutics, including novel immunotherapies, gene therapy, upcoming clinical trials and surgical advancements. The purpose is to improve the understanding of multidisciplinary treatment, learn about adjuvant therapy possibilities, raise awareness to various types of immunological therapies, and emphasize the need to treat mesothelioma as a chronic disease. Oncologists, pulmonologists, surgeons, nurses, medical students, mesothelioma advocates, patients and families across the nation will attend to exchange thoughts and ideas. The Mesothelioma Center’s Patient Advocates Karen Selby and Vanessa Blanco will participate, ensuring patients and loved ones who reach out to the organization in the coming months will receive the latest information on mesothelioma treatments. Selby, a registered nurse with a surgical and oncological background, joined The Mesothelioma Center in 2009. “It’s important for us to be there, hearing about the cutting-edge research and learni...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: 216 mesothelioma conference in california international mesothelioma conference International Symposium on Malignant Pleural Mesothelioma robert cameron UCLA Comprehensive Mesothelioma Program Source Type: news

Related Links:

Dr. Jack West reviews his top 5 abstracts in stage I-III non-small cell lung cancer, small cell lung cancer, and mesothelioma at ASCO 2018, explaining why each is poised to change the landscape of pat... Author: BeaconMedIC Added: 05/23/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Conclusions: DNA image analysis is useful for differentiating EHE from reactive mesothelial cells and high-grade carcinoma. For accurate diagnosis of EHE in effusion fluids, cytologic features should be considered together with clinical history and ancillary studies.
Source: CytoJournal - Category: Pathology Authors: Source Type: research
If you have mesothelioma and you’ve already received standard-of-care therapies, you may be considering an immunotherapy clinical trial. If you’re considering this option, a free immunotherapy teleconference is a great place to learn more. CancerCare recently hosted two one-hour education workshops featuring panels of immunotherapy experts. Part I of the teleconference presented an overview of immunotherapy. Part II of the teleconference, which is available online for free, focused exclusively on immunotherapy side effects. Understanding these issues and the role each patient plays in managing their own side ef...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusion When considering asbestos exposure, past exposure, even for short periods, might be enough to cause mesothelioma of the pleura later in life.
Source: Safety and Health at Work - Category: Occupational Health Source Type: research
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Every year, more people die from asbestos exposure than road traffic accidents in Great Britain. Many countries still continue to build with this lethal substance – but why?Hannah Devlin investigatesSubscribe and review onAcast,Apple Podcasts,Soundcloud,Audioboom andMixcloud. Join the discussion onFacebook andTwitterThe health effects of asbestos have been well documented for decades. Inhaling these fibres can cause mesothelioma, a very aggressive form of cancer with a poor prognosis. In Great Britain, more people die from this disease every year than road traffic accidents. And yet this material is still found in at...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Science Health Medicine Cancer research Medical research Society Source Type: news
Oncologists in Spain are recruiting patients for the randomized phase of the pleural mesothelioma clinical trial involving ONCOS-102, the promising immunotherapy vaccine. Optimism surrounding the trial stems from encouraging results obtained recently in the six-patient safety cohort used as a precautionary lead-in. The trial involves the vaccine in combination with standard-of-care chemotherapy for patients with inoperable disease. ONCOS-102 is a scientifically engineered adenovirus that is designed to activate a patient’s immune system to selectively target cancer cells. It is being developed by Targovax, a Scandina...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
CONCLUSIONS: GL-ONC1 was well tolerated when administered into the peritoneal cavity of patients with advanced stage PC. Efficient tumor cell infection, in-patient virus replication as well as onco-lysis were limited to treatment cycle 1. (ClinicalTrials.gov number, NCT01443260). PMID: 29773661 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Systemic chemotherapy, either before or after cytoreductive surgery, provided no improvement in long-term survival for patients with peritoneal mesothelioma, according to a recent study. The addition of systemic chemotherapy improved survival at the one-year mark, but there were no benefits at the two-, three- or five-year checkpoints. Systemic chemotherapy uses anti-cancer drugs that are injected into a vein or given by mouth. The median survival of surgical patients who received systemic chemotherapy did not improve, either. “We know surgery is the best option, and if the surgery is successful, chemotherapy may not...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusions: Targeting the epigenetic induction of DKK1 may lead to effective treatment of MM, and T3E has great potential to induce anti-MM activity.Pharmacology 2018;102:26 –36
Source: Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Allergy & Immunology | Asbestosis | Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Cardiovascular & Thoracic Surgery | Clinical Trials | Conferences | Environmental Health | Gene Therapy | Genetics | Heart | Immunotherapy | Learning | Mesothelioma | New York University | Nurses | Nursing | Students | Universities & Medical Training